Phagenesis is a medical technology company founded in 2007 and headquartered in Manchester, United Kingdom. The company focuses on developing neurostimulation devices for the treatment of neurogenic dysphagia, a condition that impairs swallowing control following strokes and other neurological events. Its work sits at the intersection of neurostimulation, medical devices, and neuroplasticity research.
The company's core product, the Phagenyx System, uses pharyngeal electrical stimulation (PES) to restore swallowing function. Clinical evidence indicates a two-fold improvement in swallowing safety, alongside faster returns to oral nutrition and reduced hospital stays. The technology is supported by more than 30 clinical publications.
Phagenesis raised $42 million in a Series D funding round, reflecting sustained investment in its approach to treating a condition that affects a significant number of patients with neurological injuries. The company operates within the medical technology, healthcare, and neurology sectors.
